ProQR Therapeutics’ (PRQR) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of ProQR Therapeutics (NASDAQ:PRQR) in a research note released on Thursday,Benzinga reports. They currently have a $10.00 price target on the biopharmaceutical company’s stock.

Several other brokerages also recently weighed in on PRQR. StockNews.com downgraded shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 28th. Raymond James upgraded shares of ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their price objective for the stock from $6.00 to $14.00 in a research note on Tuesday, October 29th. Finally, Chardan Capital restated a “buy” rating and set a $4.00 target price on shares of ProQR Therapeutics in a research report on Thursday. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $7.60.

ProQR Therapeutics Stock Performance

Shares of PRQR stock opened at $2.83 on Thursday. ProQR Therapeutics has a fifty-two week low of $1.61 and a fifty-two week high of $4.62. The firm has a market capitalization of $231.15 million, a PE ratio of -8.84 and a beta of 0.24. The stock’s 50-day simple moving average is $3.40 and its 200-day simple moving average is $2.40.

Institutional Investors Weigh In On ProQR Therapeutics

Several hedge funds have recently bought and sold shares of PRQR. Privium Fund Management B.V. increased its holdings in shares of ProQR Therapeutics by 4.4% during the 2nd quarter. Privium Fund Management B.V. now owns 5,580,725 shares of the biopharmaceutical company’s stock valued at $9,208,000 after purchasing an additional 236,279 shares in the last quarter. OneDigital Investment Advisors LLC grew its position in ProQR Therapeutics by 37.0% during the third quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 15,550 shares during the period. Finally, BNP Paribas Financial Markets grew its position in ProQR Therapeutics by 14.2% during the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 7,300 shares during the period. Hedge funds and other institutional investors own 32.65% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).